making improvements in life - qiagen · molecular diagnostics portfolio with attractive potential...

Sample & Assay Technologies

Commerzbank German Investment Seminar 2013Roland Sackers Chief Financial OfficerJanuary 15, 2013

Making improvements in life possible

Sample & Assay Technologies Forward looking statements

Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statementswithin the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities ExchangeAct of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategyor operating results, including without limitation its expected operating results, are forward-looking, such statements are based oncurrent expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but arenot limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations,regulatory processes and dependence on logistics), variability of operating results and allocations between business segments, thecommercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics,women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers andstrategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products(including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); ourability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutionsand producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect ourproducts from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies andbusinesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S.Securities and Exchange Commission (SEC).

Regulation G: Some of the slides in this presentation contain certain summary information about QIAGEN N.V.’s sales, gross profit,operating income, net income, and earnings per share, which information is presented on a “non-GAAP financial measures” basisrather than in accordance with U.S. generally accepted accounting principles (GAAP). Please review QIAGEN’s press releases,which can be found in the Investor Relations section of QIAGEN’s webpage under www.QIAGEN.com, for information on theCompany’s operating income, net income, and earnings per share presented on a GAAP basis. Such GAAP-basis information willalso be contained in the Company’s reports on Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities andExchange Commission.

Commerzbank German Investment Seminar, January 15, 2013 2


3

Broad product offering with common purpose

From biological sample to clinical result

3

SAMPLE Technologies ASSAY TechnologiesBIOLOGICAL SAMPLE

VALUABLE MOLECULAR

INFORMATION



4

World leader in Sample & Assay Technologies

Enable access to molecular information Biological sample to digital result

> 500 core products Consumable kits and instruments

> 500,000 customers worldwide Molecular Diagnostics Applied Testing Pharma Academia

Innovative power ~2,500 patents

Healthy financial position Strong cash conversion Improving margins

2011 key figures (In $ millions)

Net sales 1,169 + 4% (CER)

Adjusted operating income 319.6 +4%

Adjusted net income 234.4 +5%

Employees ~3,900

4

CER – Constant exchange rates


Sample & Assay Technologies World leader in Sample & Assay Technologies

Enable access to molecular information

Address broad range of customer needs

Expanding global presence

Healthy financial position

QIAGEN at a glance

48%

8%

20%

24%

Molecular Diagnostics

Applied Testing

2012 9M net sales: $908 million

Pharma

Academia



Instruments

Comprehensive product range to support workflows

2012 9M net sales: $908 million

Leading portfolio of molecular tests for use with range of instruments

Consumables

87% 13%



2012 9M sales Key customers Product highlights

~48% Reference labs

Hospitals

Prevention: HPV, QuantiFERON-TB

Profiling: Infectious diseases

Personalized Healthcare: Companion diagnostics

Point of Need: AmniSure, ESE

~8% Forensic labs

Industrial

Governments

Human identification

Veterinary medicine

Food safety

~20% Big Pharma

Specialty / Biotech

CROs

GeneGlobe: Gene and pathway analysis

Biomarkers

~24% Government research

Academic labs

Life sciences research

Translational medicine

Supporting >500,000 customers worldwide

Applied Testing

Pharma

Academia




8

Strategic initiatives to drive growth and innovation

Drive platform success Roll out QIAsymphony worldwide Advance QIAensemble strategy

Leverage leadership in Sample & Assay Technologies

8

Add content New tests across all customer classes

Broaden geographic presence Top emerging markets

Grow efficiently and effectively Sustained growth Leverage synergies Best-in-class teams


Applied Testing

Pharma

Academia



Prevention

Molecular Diagnostics portfolio with attractive potential

QuantiFERON-TB

AmniSure and ESE

therascreen companion diagnostics

Expanding infectious disease menu

Applied Testing

Pharma

Academia


Personalized Healthcare

Point of Need Profiling


Sample & Assay Technologies QIAsymphony RGQ: New era of automation

Most versatile molecular testing system

Achieved >200 new placements in 2012 End-2011 level: >550 systems Rising average consumables pull-through

Global rollout gaining momentum

Improving value proposition

Development projects in all customer classes

QIAsymphony SP Automates sample prep

QIAsymphony AS Automates assay setup

Sample Result

Rotor-Gene Q Detection Analysis

QIAsymphony family

QIAGEN addressing needs for lab automation and integration


Sample & Assay Technologies Many R&D milestones achieved in 2012

Key regulatory decisions Type Status

Rotor-Gene Q MDx Real-time PCR instrument 510(k)

therascreen KRAS (Erbitux) Companion diagnostic in metastatic colorectal cancer PMA

artus Influenza Influenza test 510(k)

therascreen BRAF Biomarker test for melanoma CE IVD

careHPV Low-cost HPV test for developing countries sFDA

Key regulatory submissions Type Status

therascreen EGFR (afatinib) Companion diagnostic in non-small cell lung cancer PMA

QuantiFERON CMV Cytomegalovirus (CMV) infections in transplant patients 510(k)


Sample & Assay Technologies All stakeholders benefit from Personalized Healthcare

Payors Cost savings

Physicians Confidence in decisions

Patients Better medicines

Pharma companies Value creation

Providers of diagnostics New market opportunities

12Commerzbank German Investment Seminar, January 15, 2013 12

Sample & Assay Technologies U.S. KRAS market conversion progressing well

Oncologists demanding therascreen test Designated teams Awareness campaigns NCCN guidelines Medical Advisory Board

~ 110,000

~ 75,000

~ 45,000

Expansionopportunities

End-2012QIAGEN share1

U.S. colorectal cancer patients(Eligible for KRAS testing)

Establishing therascreen brand for wave of companion diagnostics

Complementary U.S. market conversion initiatives

Labs promoting therascreen test Drive test adoption Co-marketing programs Sales training Future tests on platform

CurrentKRAStesting

1 Annualized estimate



Project Partner Indication Biomarker Status

Erbitux (cetuximab)

Colorectalcancer KRAS U.S. regulatory approval in July 2012

Vectibix(panitumumab)

Colorectalcancer KRAS U.S. submission (PMA) in H2 2011

PF-00299804(dacomitinib)

Lung cancer(NSCLC) KRAS In development

Iressa(gefitnib) AstraZeneca Lung cancer

(NSCLC) EGFR CE-IVD kit in Europe and other non-U.S. markets

(afatinib)Lung cancer(NSCLC) EGFR U.S. submission (PMA) in H2 2012

Early-stage compound Blood cancer JAK2 In development

Various projects Not disclosed Various In development

Not disclosed Confidential Non-oncology Confidential In development

Industry-leading portfolio of co-development projects

Selected co-development projects

Covering multiple technologies: PCR, panels and NGS options


Sample & Assay Technologies QuantiFERON-TB: Expanding use in key target groups

Latent tuberculosis (TB)

A key driver of latent TB testing: Growing use of biological medicines

1 in 3 people worldwide…

has latent TB

And of those with latent TB…

1 in 10 develop active TB

Latent TB test target groups

Public health TB control

Employmentscreening

Medical staffFire and police

Communityliving

Correctional sitesMilitaryUniversitiesNursing homes

Immuno-suppressedpatients

TB risk detection

Clinicaltrials

Patient selection



Single visit, results in <24 hours

Objective, high specificity: 99.2%

Not affected by BCG vaccine

Tuberculin Skin Test (1890s) QuantiFERON-TB Gold (2000s)

QuantiFERON-TB: Conversion to new gold standard

2-4 visits required

Subjective, low specificity: 65.9%

Not reliable for TB-vaccinated people

Latent TB testing: >$1 billion total addressable market potential


Sample & Assay Technologies Preparing to launch first NGS workflows in 2013

Assay Technologies

NGS workflow

Competitive portfolio

GeneGlobecapabilities

Global leader in Sample Technologies

Automation options

Bioinformatics from QIAGEN

and SAP

Sample Technologies

Data alignment /

analysisNGS runLibrary

preparationTarget

enrichmentDNA / RNA

preprocessing

Primary sample to purified

DNA / RNA

Sample-to-result workflows

Flexibility and scalability

Reliable and accurate results

Using many proven QIAGEN technologies

Cost competitive

Key features

QIAsymphony NGS version

QIAcube version


Sample & Assay Technologies Expanding geographic presence

Full-year 2011 net sales by region

Targeting expansion in Eastern Europe and Latin America

48%

34%

17%Asia-Pacific /

Japan+8% CER

Europe / Middle East /

Africa+7% CER

Americas+2% CER

Brazil

Russia Future opportunityIndia 2011 direct entryChina

South Korea

Turkey

Mexico

Top 7 emerging markets:12% of net sales / +21% CER

CER – Constant exchange ratesEMEA – Europe / Middle East / Africa



Strategy Initiatives

Accelerate organic and strategic growth

New product launchesQIAsymphony rolloutExpansion in emerging markets

Deliver efficiency and effectiveness Maximize resource allocation

Employer of choice Best talent and top teams

Enhance customer experience Exceed customer expectations

Perspectives on 2013

19

Executing on 2013 initiatives to drive growth and innovation at a faster pace



QIAsymphony global rollout Test menu expansion

Companion diagnostics U.S. market approvals Translational medicine Applied Testing

High-growth markets

Freeing up resources to reinvest

Returning QIAGEN to a faster growth profile

Reallocate resources and personnel, selective reductions

Project planning Restructuring charge1

Implementing projects: R&D portfolio Manufacturing Pricing optimization Global procurement Organizational

excellence Restructuring charge1

Completed Ongoing

Efficiency gains(Q4 2011 – Q1 2012)

Operational improvements(Start: Q1 2012)P

hase

Topi

csS

tatu

s

Selected investments

2012 goal: Free up $50 million to reinvest in strategic initiatives

1 Restructuring charges of $75 million taken in Q4 2011 and $11 million in Q1 2012, further charges may be taken in 2012



Track record of innovation and growth

Robust development pipeline Strong free cash flow to support expansion

World leader in Sample & Assay Technologies

Driving the dissemination of molecular testing

Key considerations: Strong growth potential

Attractive and growing markets

Building leadership in Molecular Diagnostics Highly competitive offering in Academia, Pharma and Applied Testing

Capitalizing on diverse growth opportunities

Pioneer in Personalized Healthcare Expansion into high-growth markets


making improvements in life - qiagen · molecular diagnostics portfolio with attractive potential...

Documents